Skip to main content

Table 1 Study characteristics

From: Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: A systematic review and meta-analysis

 

Psychotherapy

Medication

Diagnosis

Mean age of sample

% female in sample

N se

Treatment duration (weeks)

N rand

Country

Browne 2002[26]

IPT

Sertraline (SSRI)

Dys, DD

42.2

68

12

24

476

Canada

deMello 2001[27]

IPT

Moclobemide

Dys, DD

38.8

80

16

32

35

Brazil

Keller 2000[28]

CBASP

Nefazodone

cMD, rec, DD

43.0

65

16

12

453

USA

Kocsis 2009[13]

CBASP/BSP

SSRIs

cMD, rec, DD

45.4

55

16/18

12

491

USA

Markowitz 2005[29]

IPT

Sertraline (SSRI)

Dys

42.3

63

16

16

45

USA

Miller 1999[30]

CBT

Amitriptyline/Desipramine

Dys

37.4

81

40

20

26

USA

Ravindran 1999[31]

CBT

Sertraline (SSRI)

Dys

38.0

58

12

12

47

Canada

Schramm 2008[32]

IPT

Sertraline (SSRI)/Amitriptyline

cMD, DD

42.8

67

15

5

45

Germany

  1. N se = number of psychotherapy sessions; N rand = patients randomized to relevant study arms; IPT = Interpersonal Psychotherapy; CBASP = Cognitive Behavioural Analysis System of Psychotherapy; BSP = Brief Supportive Psychotherapy; CBT = Cognitive Behavioural Therapy; Dys = dysthymia; DD = double depression; cMD = chronic major depression; rec = recurrent depression without complete remission between episodes.